NEW YORK (AP) — Shares of Valeant, already down 70 percent this year, are plunging in premarket trading on a report that it hid from insurers its ties to a mail-order pharmacy that sold its drugs.
The Wall Street Journal is reporting that prosecutors are looking into the possibility that the Canadian pharmaceutical, already subject to several federal probes, covered up its ties to Philidor Rx Services.
Valeant cut its ties to Philidor in October following accusations that it was a phantom pharmacy used solely to boost Valeant’s sales.
The report sent shares of Valeant Pharmaceuticals International, Inc. down 9 percent before the opening bell Thursday.
The company says it’s been cooperating with investigators since it disclosed an investigation by the United States Attorney’s Office for the Southern District of New York in October.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
